Alzheimer's Disease

A plasma phosphorylated-tau 217 immunoassay offers comparative diagnostic accuracy for Alzheimer’s disease pathologies to that of cerebrospinal fluid biomarkers, with a reduced need for advanced confirmatory testing.

Individuals with hearing loss may be at an increased risk for developing incident dementia, with additional risk in those people who do not use hearing aids.

Individuals diagnosed with coronary heart disease have an increased risk for developing all-cause dementia, Alzheimer’s disease, and vascular dementia in later life, particularly if diagnosed before the age of 45 years.

Huntington’s disease has no effective treatment to prevent progression and its involuntary motor symptoms but, in this 75-year-old patient, daily memantine has prevented chorea and disease progression for 5 years.

Clinical course and autopsy findings from two patients treated with aducanumab for Alzheimer's disease, shedding light on the time course of amyloid lowering and the potential impact of co-pathology on clinical response.

Emerging biomarkers and disease-modifying therapies for Alzheimer’s disease promise significant changes in how the condition is diagnosed and managed.

Guide yourself through this transition with our education program, led by world renowned experts and covering the biggest international conferences.

This content is intended for healthcare professionals outside of the UK.

PET biomarkers are fast becoming critical in the new era of disease modification for Alzheimer’s disease. Techniques around amyloid and tau require the expertise of nuclear medicine and radiology physicians to investigate and interpret PET scans in clinical settings. This program examines current and emerging biomarkers and assists in identifying patterns from different PET tracers in an interactive perceptual learning environment.

Animated, interactive expert-led website focusing on  neuroinflammation and its role in the development of Alzheimer’s disease.

This program is not available to users in the UK and US.